Harrow, Inc. (HROW)
Market Cap | 2.02B |
Revenue (ttm) | 154.15M |
Net Income (ttm) | -33.58M |
Shares Out | 35.48M |
EPS (ttm) | -0.95 |
PE Ratio | n/a |
Forward PE | 237.42 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 408,148 |
Open | 56.50 |
Previous Close | 56.42 |
Day's Range | 55.57 - 57.72 |
52-Week Range | 7.60 - 59.23 |
Beta | 0.75 |
Analysts | Strong Buy |
Price Target | 55.00 (-3.47%) |
Earnings Date | Nov 11, 2024 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e... [Read more]
Financial Performance
In 2023, Harrow's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is a decrease of -3.47% from the latest price.
News
I Am Banking On The Silver Tsunami With Big Dividends
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
Harrow Relaunches TRIESENCE®
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable su...
Harrow Inc (HROW) Shares Up 3.26% on Oct 2
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.
Harrow Announces Nashville Expansion
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer o...
Harrow to Present at Three Investor Conferences in September in New York
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three inv...
Harrow: Bulls On Parade
Harrow stock is reaching new highs with significant short interest, but operational strength is driving a covering rally. Harrow is an eye care pharmaceutical company targeting the North American mark...
Harrow Announces Second Quarter 2024 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the second quarter and six months ended June 30, 2024...
Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks
I have a diversified portfolio of stocks, funds, and bonds. My stocks are primarily dividend paying value stocks. One can find dividend stocks with superior estimated total returns by comparing their ...
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ende...
Harrow to Attend 2024 ASRS Annual Meeting
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Soc...
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement w...
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in...
Harrow Provides TRIESENCE® Relaunch Update
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three com...
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first pati...
The 'Undercovered' Dozen From May 2024
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in ...
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE...
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves...
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference...
Harrow Announces First Quarter 2024 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company a...
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, H...
Harrow: Merits A Buy On Sales Potential
Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expect...
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has cripp...
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ende...
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of i...